Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Consumer Perspectives on Access to Direct‐to‐Consumer Genetic Testing: Role of Demographic Factors and the Testing Experience
Gollust, Sarah E. , Gray, Stacy W. , Carere, Deanna Alexis , Koenig, Barbara A. , McGuire, Amy , Sharp, Richard R. , Spector‐Bagdady, Kayte , Wang, Na , Roberts, J. Scott , Group, for the PGen Study, Roberts, J. Scott , Lehmann, Lisa Soleymani , Green, Robert C. , Group, for the PGen Study, Sharp, Richard R , Gray, Stacy W

Mayo Clinic

The Milbank Quarterly | June 7, 2017 | Volume: 95 | Issue: 2 | Pages: 291-318

10.1111/1468-0009.12262 | PMID 28589610 Get It

Policy Points: The policy context of direct‐to‐consumer personal genomic testing (DTC‐PGT) has been evolving over the last decade, with little empirical data available about consumers’ perspectives. A majority of consumers of DTC‐PGT supported expanded access to services and their integration into the medical context and opposed more governmental regulation. Consumers’ attitudes about access to services and regulation did not vary based on the specific genetic risk information they received from companies, but may vary based on whether consumers perceived their DTC experience negatively. ContextWhile policymakers have been considering the appropriateness of direct‐to‐consumer personal genomic testing (DTC‐PGT) for more than a decade, there is little empirical data on consumers’ views regarding the regulation of these products. No research has assessed whether consumers’ personal experience with testing is related to their views about access to and regulation of DTC tests.MethodsData were analyzed from the PGen Study, a longitudinal prospective cohort of DTC‐PGT customers of 23andMe (n = 564) and Pathway Genomics (n = 377; total N = 941). Consumers were sent an electronic survey before receiving genetic test results and again 6 months after receipt of results.FindingsAt the 6‐month follow‐up, more than 80% of participants believed that people have a right to access genetic information directly, that parents should be able to get DTC‐PGT testing for their children, and that genetic information should be kept private. Participants supported health insurance coverage of PGT (60%), wider availability of PGT (68%), and inclusion of genetic information in medical records (63%). Participants were less supportive of government regulation (28%) and restricting testing to clinical settings (14%). Conservative political ideology was associated with less support for government regulation (P < 0.001), as was feeling more confident in one's genetic knowledge (P < 0.05). Participants’ level of computed genetic risk for common diseases, as indicated by their actual test results received from companies, showed no relationship with attitudes. However, those who perceived that they had received elevated risk results expressed lower support for expanded availability and incorporation of PGT into health care (P < 0.01). Those who reported being upset by their genetic test results were less likely to endorse access to DTC products without a medical professional (P < 0.01).ConclusionsPGT consumers supported expanded access to these services and opposed additional regulation. Users who had a negative personal experience with PGT testing were less supportive of expanded availability without a medical professional.
“It’s important, but…”: Perceived Barriers and Situational Dependencies to Social Contact Preferences of Nursing Home Residents
Abbott, Katherine , Bangerter, Lauren R. , Humes, Sarah, Klumpp, Rachel, Haitsma, Kimberly Van, Abbott, Katherine M

Mayo Clinic

The Gerontologist | June 6, 2017 | Volume: 58 | Issue: 6 | Pages: 1126-1135

10.1093/geront/gnx109 | PMID 28645167 Get It

Polycystic Kidney Disease without an Apparent Family History
Iliuta, Ioan-Andrei, Kalatharan, Vinusha , Wang, Kairong , Gall, Émilie Cornec-Le , Conklin, John , Pourafkari, Marina, Borgo, Alessia C., He, Ning , Song, Xuewen , Heyer, Christina M., Senum, Sarah R. , Paterson, Andrew D. , Harris, Peter C. , Khalili, Korosh , Pei, York , Cornec-Le Gall, Emilie, Ting, Ryan S. , Chen, Chen , Hwang, Young‐Hwan , Harris, Peter C , Paterson, Andrew , Senum, Sarah R , Cornec-Le Gall, Emilie

Mayo Clinic

Journal of the American Society of Nephrology | May 18, 2017 | Volume: 28 | Issue: 9 | Pages: 2768-2776

10.1681/asn.2016090938 | PMID 28522688 Get It

The absence of a positive family history (PFH) in 10%–25% of patients poses a diagnostic challenge for autosomal dominant polycystic kidney disease (ADPKD). In the Toronto Genetic Epidemiology Study of Polycystic Kidney Disease, 210 affected probands underwent renal function testing, abdominal imaging, and comprehensive PKD1 and PKD2 mutation screening. From this cohort, we reviewed all patients with and without an apparent family history, examined their parental medical records, and performed renal imaging in all available parents of unknown disease status. Subsequent reclassification of 209 analyzed patients revealed 72.2% (151 of 209) with a PFH, 15.3% (32 of 209) with de novo disease, 10.5% (22 of 209) with an indeterminate family history, and 1.9% (four of 209) with PFH in retrospect. Among the patients with de novo cases, we found two families with germline mosaicism and one family with somatic mosaicism. Additionally, analysis of renal imaging revealed that 16.3% (34 of 209) of patients displayed atypical PKD, most of which followed one of three patterns: asymmetric or focal PKD with PFH and an identified PKD1 or PKD2 mutation (15 of 34), asymmetric and de novo PKD with proven or suspected somatic mosaicism (seven of 34), or focal PKD without any identifiable PKD1 or PKD2 mutation (eight of 34). In conclusion, PKD without an apparent family history may be due to de novo disease, missing parental medical records, germline or somatic mosaicism, or mild disease from hypomorphic PKD1 and PKD2 mutations. Furthermore, mutations of a newly identified gene for ADPKD, GANAB , and somatic mosaicism need to be considered in the mutation-negative patients with focal disease.
Image Gallery: A case of pemphigus vulgaris following Simulium spp. (Diptera) bites
Wambier, Carlos Gustavo , Struecker, T.A., Durski, L.N., Wambier, Sarah P.F., Cappel, Mark A. , Vernal, Sebastián , Araújo, A.G. de, Wambier, Sarah Perillo de Farias , Roselino, Ana Maria Ferreira , Wambier, Carlos G

Mayo Clinic

British Journal of Dermatology | May 15, 2017 | Volume: 176 | Issue: 5 | Pages: e100-e100

10.1111/bjd.15393 | PMID 28504401 Get It

Attitudes, Beliefs, Practices, and Concerns Among Clinicians Prescribing Opioids in a Large Academic Institution
Ebbert, Jon O. , Philpot, Lindsey M. , Clements, Casey M. , Lovely, Jenna K. , Nicholson, Wayne T. , Jenkins, Sarah M. , Lamer, Tim J. , Gazelka, Halena M. , Philpot, Lindsey M

Mayo Clinic

Pain Medicine | May 10, 2017 | Volume: 19 | Issue: 9 | Pages: 1790-1798

10.1093/pm/pnx140 | PMID 29177439 Get It

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors
Burris, Howard A. , Infante, Jeffrey R., Ansell, Stephen M. , Weiss, Geoffrey R. , Villalobos, Víctor M. , Šikić, Branimir I. , Northfelt, Donald W. , Carson, William E. , Hawthorne, Thomas, Davis, Thomas A., Yellin, Michael , Keler, Tibor , Infante, Jon , Nemunaitis, John J, Hawthorne, Thomas R, Yellin, Michael J, Bullock, Timothy, Nemunaitis, John , Taylor, Matthew H. , Bullock, Timothy N J , Carson, William E , Infante, Jon

Mayo Clinic

Journal of Clinical Oncology | May 2, 2017 | Volume: 35 | Issue: 18 | Pages: 2028-2036

10.1200/jco.2016.70.1508 | PMID 28463630 Get It

Purpose CD27, a costimulatory molecule on T cells, induces intracellular signals that mediate cellular activation, proliferation, effector function, and cell survival upon binding to its ligand, CD70. Varlilumab is a novel, first-in-class, agonist CD27 antibody that stimulates the CD27 pathway, which results in T-cell activation and antitumor activity in tumor models. This first-in-human, dose-escalation and expansion study evaluated the safety, pharmacology, and activity of varlilumab in patients with advanced solid tumors. Methods In a 3 + 3 dose-escalation design (n = 25), patients received a single dose of varlilumab (0.1, 0.3, 1.0, 3.0, or 10 mg/kg intravenously) with a 28-day observation, followed by up to five multidose cycles (one dose per week for 4 weeks), depending on tumor response. Expansion cohorts were initiated at 3.0 mg/kg in patients with melanoma (n = 16) and renal cell carcinoma (RCC; n = 15). Primary objectives were to assess the safety and the maximum tolerated and optimal biologic doses of varlilumab. Secondary objectives were to evaluate the pharmacokinetics, pharmacodynamics, and clinical antitumor activity of varlilumab. Results Exposure to varlilumab was linear and dose proportional across dose groups. Only one patient experienced a dose-limiting toxicity—grade 3 transient asymptomatic hyponatremia at the 1.0-mg/kg dose level. Treatment-related adverse events were generally grade 1 or 2 in severity. Evidence of biologic activity consistent with CD27 stimulation—chemokine induction, T-cell stimulation, regulatory T cell depletion—was observed at all dose levels. A patient with metastatic RCC experienced a partial response (78% shrinkage, progression-free survival > 2.3 years). Eight patients experienced stable disease > 3 months, including a patient with metastatic RCC with progression-free survival of > 3.9 years. Conclusion Dose escalation of varlilumab to 10 mg/kg was well tolerated without identification of a maximum tolerated dose. Varlilumab was biologically and clinically active.
Intersection of diverse neuronal genomes and neuropsychiatric disease: The Brain Somatic Mosaicism Network
McConnell, Michael J. , Moran, John V. , Abyzov, Alexej , Akbarian, Schahram , Bae, Taejeong , Cortés‐Ciriano, Isidro , Erwin, Jennifer A. , Fasching, Liana , Flasch, Diane A. , Freed, Donald , Ganz, Javier , Jaffe, Andrew E. , Kwon, Min‐Seok , Lodato, Michael A. , Mills, Ryan E. , Paquola, Apuã C.M. , Rodin, Rachel E. , Rosenbluh, Chaggai , Šestan, Nenad , Sherman, Maxwell A. , Shin, Joo Heon , Song, Saera , Straub, Richard E. , Thorpe, Jeremy , Weinberger, Daniel R. , Urban, Alexander E. , Zhou, Bo , Lehner, Thomas , Senthil, Geetha , Chess, Andrew , Courchesne, Eric , Gleeson, Joseph G. , Kidd, Jeffrey M. , Park, Peter J., Pevsner, Jonathan , Vaccarino, Flora M. , Network, Brain Somatic Mosaicism, Bekiranov, Stefan , Bohrson, Craig L. , Burbulis, Ian , Chronister, William D., Coppola, Gianfilippo , Daily, Kenneth , D’Gama, Alissa M. , Emery, Sarah B., Frisbie, Trenton J., Gao, Tianliuyun , Gulyás-Kovács, Attila, Haakenson, Mark F., Keil, Jason M. , Lam, Mandy M. , Mathern, Gary W. , Omberg, Larsson , Peters, Mette A. , Pochareddy, Sirisha , Pramparo, Tiziano , Sanavia, Tiziana , Wang, Meiyan , Wierman, Margaret E. , Wolpert, Matthew J., Woodworth, Mollie B. , Zhao, Xuefang , Zhou, Weichen , Kwan, Kenneth Y , Lodato, Michael A , Mills, Ryan E , Paquola, Apua C M , Rodin, Rachel E , Rosenbluh, Chaggai , Sestan, Nenad , Shin, Joo Heon , Song, Saera , Straub, Richard E , Urban, Alexander E , Zhou, Bo , Gage, Fred H , Lehner, Thomas , Senthil, Geetha , Chess, Andrew , Courchesne, Eric , Kidd, Jeffrey M , Pevsner, Jonathan , Vaccarino, Flora M , McConnell, Michael J. , Walsh, Christopher A. , Gleeson, Joseph G. , Network, Brain Somatic Mosaicism, Barton, Alison R. , Kopera, Huira C. , Lee, Eunjung A , Marquès‐Bonet, Tomàs , Moldovan, John B. , Oetjens, Matthew T. , Ratan, Aakrosh , Shi, Lei , Škarica, Mario , Wang, Jia , Wang, Yifan , Abyzov, Alexej , Bae, Taejeong , Akbarian, Schahram

Mayo Clinic

Science | April 27, 2017 | Volume: 356 | Issue: 6336 | Pages: No page available

10.1126/science.aal1641 | PMID 28450582 Get It

Single-cell diversity in the brain The cells that make up an organism may all start from one genome, but somatic mutations mean that somewhere along the line of development, an organism's individual cellular genomes diverge. McConnell et al. review the implications and causes of single-cell genomic diversity for brain function. Somatic mutations caused by mobile genetic elements or errors in DNA repair may underlie certain neuropsychiatric disorders. Science , this issue p. eaal1641
Serologic Testing for Zika Virus: Comparison of Three Zika Virus IgM-Screening Enzyme-Linked Immunosorbent Assays and Initial Laboratory Experiences
Granger, Dane, Hilgart, Heather, Misner, Lori, Christensen, Jaime, Bistodeau, Sarah, Palm, Jennifer, Strain, Anna K., Konstantinovski, Marja, Liu, Dakai , Tran, Anthony, Theel, Elitza S.

Mayo Clinic

Journal of Clinical Microbiology | April 27, 2017 | Volume: 55 | Issue: 7 | Pages: 2127-2136

10.1128/jcm.00580-17 | PMID 28446573 Get It

ABSTRACT Serologic evaluation for Zika virus (ZIKV) infection currently includes an initial screen using an anti-ZIKV IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) followed by supplemental testing of specimens with nonnegative results by a plaque reduction neutralization test (PRNT). We compared the performance characteristics of three ELISAs for the detection of IgM class antibodies to ZIKV, including the Centers for Disease Control and Prevention (CDC) Zika MAC-ELISA, the InBios ZIKV Detect MAC-ELISA, and the Euroimmun anti-Zika Virus IgM ELISA. Additionally, we present our initial experiences with ZIKV serologic testing from a national reference laboratory perspective. Using both retrospectively and prospectively collected specimens from patients with possible ZIKV infection, we show that the CDC and InBios MAC-ELISAs perform comparably to each other, with positive agreement, negative agreement, and interrater kappa values ranging from 87.5% to 93.1%, 95.7% to 98.5%, and 0.52 to 0.83, respectively. In contrast, comparison of the Euroimmun ZIKV ELISA to either the CDC or InBios MAC-ELISAs resulted in positive agreement, negative agreement, and interrater kappa values ranging from 17.9% to 42.9%, 91.7% to 98.6%, and 0.10 to 0.39, respectively. Among the 19 prospective samples submitted for PRNT, nine were negative, eight specimens had neutralizing antibodies to a flavivirus (unable to be identified), and one sample each was confirmed for ZIKV or dengue virus infection. This study highlights the ongoing challenges associated with serologic diagnosis of ZIKV infection. Although the availability of a commercial serologic test for ZIKV has greatly expanded the national capacity for such testing, the need to further characterize and improve these assays, particularly with regard to specificity, remains.